Literature DB >> 11015427

Vancomycin-intermediate Staphylococcus aureus in Korea.

M N Kim1, C H Pai, J H Woo, J S Ryu, K Hiramatsu.   

Abstract

Recent reports on some methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin have been a major concern in Korea because of the widespread use of vancomycin due to a high prevalence of MRSA in the country. We describe a 45-year-old man with long-standing pelvic abscess due to MRSA. In spite of vancomycin and teicoplanin treatment for a long period of time, the patient died from MRSA sepsis. The blood culture isolate of MRSA exhibited reduced susceptibility to vancomycin (MIC, 8 microg/ml). This is the first report of a vancomycin-intermediate S. aureus case from Korea.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11015427      PMCID: PMC87500     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study.

Authors:  J H Song; N Y Lee; S Ichiyama; R Yoshida; Y Hirakata; W Fu; A Chongthaleong; N Aswapokee; C H Chiu; M K Lalitha; K Thomas; J Perera; T T Yee; F Jamal; U C Warsa; B X Vinh; M R Jacobs; P C Appelbaum; C H Pai
Journal:  Clin Infect Dis       Date:  1999-06       Impact factor: 9.079

2.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

Authors:  K Sieradzki; R B Roberts; S W Haber; A Tomasz
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

3.  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-08-22       Impact factor: 17.586

4.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

5.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

6.  Korean Nationwide Surveillance of Antimicrobial Resistance of bacteria in 1997.

Authors:  Y Chong; K Lee; Y J Park; D S Jeon; M H Lee; M Y Kim; C H Chang; E C Kim; N Y Lee; H S Kim; E S Kang; H C Cho; I K Paik; H S Lee; S J Jang; A J Park; Y J Cha; S H Kang; M H Lee; W Song; J H Shin
Journal:  Yonsei Med J       Date:  1998-12       Impact factor: 2.759

7.  Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

Authors:  H Hanaki; K Kuwahara-Arai; S Boyle-Vavra; R S Daum; H Labischinski; K Hiramatsu
Journal:  J Antimicrob Chemother       Date:  1998-08       Impact factor: 5.790

8.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

9.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

  9 in total
  38 in total

Review 1.  Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods.

Authors:  Catherine Liu; Henry F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

2.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Akira Iwamoto; Jian-Qi Lian; Hui-min Neoh; Toshiki Maruyama; Yataro Horikawa; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.

Authors:  M H Kollef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

5.  First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand.

Authors:  S Trakulsomboon; S Danchaivijitr; Y Rongrungruang; C Dhiraputra; W Susaemgrat; T Ito; K Hiramatsu
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

6.  Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.

Authors:  Miki Matsuo; Longzhu Cui; Jeeyoung Kim; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

7.  DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus.

Authors:  Longzhu Cui; Jian-Qi Lian; Hui-Min Neoh; Ethel Reyes; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.

Authors:  S Al-Obeid; Q Haddad; A Cherkaoui; J Schrenzel; P François
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

9.  Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.

Authors:  Ji Young Lee; Won Sup Oh; Kwan Soo Ko; Sang Taek Heo; Chi Sook Moon; Hyun Kyun Ki; Sungmin Kiem; Kyong Ran Peck; Jae Hoon Song
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

10.  Methicillin and Vancomycin Resistant S. aureus in Hospitalized Patients.

Authors:  Poonam Sood Loomba; Juhi Taneja; Bibhabati Mishra
Journal:  J Glob Infect Dis       Date:  2010-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.